Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697085 | 0.91 | MET (0.83) | METCDKL5 | |
| SCHEMBL1697083 | 0.91 | MET (1.00) | METCDKL5KCNH2 | |
| SCHEMBL1697091 | 0.91 | MET (0.82) | METCDKL5 | |
| Capmatinib SCHEMBL29370685 | 0.90 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL1426819 | 0.90 | MET (1.00) | METCDKL5KCNH2 | |
| SCHEMBL19140598 | 0.90 | MET (0.83) | METCDKL5KCNH2 | |
| SCHEMBL4515760 | 0.90 | MET (0.81) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL29429714 | 0.90 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL31061495 | 0.89 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL1427109 | 0.89 | MET (0.98) | METCDKL5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137650-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION | 2016-05-19 | — | — | US | claimed |
| US-20130345224-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2013-12-26 | — | — | US | claimed |
| EP-2531509-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | Incyte Corporation (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2011162835-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | claimed |
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-09-01 | — | — | US | claimed |
| US-10919901-B2 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919901-B2 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200247811-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION | 2020-08-06 | — | — | US | disclosed |
| US-20200247811-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION | 2020-08-06 | — | — | US | disclosed |
| US-10472367-B2 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | INCYTE INCORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472367-B2 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | INCYTE INCORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180370977-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE HOLDINGS CORPORATION | 2018-12-27 | — | — | US | disclosed |
| US-8487096-B2 | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors | INCYTE CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487096-B2 | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors | INCYTE CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487096-B2 | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors | INCYTE CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2531509-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | Incyte Corporation (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011162835-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370977-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
| US-20130345224-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
| US-10472367-B2 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
| US-20200247811-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
| US-10919901-B2 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
| US-20160137650-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | MET, RET, ERBB2 | MET 1/4885CDKL5 498/4885KCNH2 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.